-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CKD-516 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CKD-516 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CKD-516 in Solid Tumor Drug Details: CKD-516 (NOV-120401) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navicixizumab in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navicixizumab in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Navicixizumab in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:Navicixizumab (OMP-305B83)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – REACT
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry REACT Drug Details REACT is under development for the treatment of chronic kidney disease,...
-
Analyst Opinions
Advanced Genomics – Key Disruptive Forces to Transform Health and Wellness
Advances in genomics have revolutionized approaches to healthcare and precision medicine. The major drivers of genomics include personalized medicine, customized genetic counseling, genetic predisposition identification, accurate disease diagnosis, disease prevention, and optimized treatments. Advances in genomics are significantly reducing the cost of genome sequencing. Genomic techniques not only help in understanding the nature of the virus to trace its potential origins but also aids in tracking disease outbreaks. The Advanced Genomics FutureTech Series report categorizes 30+ disruptive forces in genomics...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic Kidney Disease (Chronic Renal Failure) is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue, weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease pipeline drugs market research report provides comprehensive information on the Chronic Renal Failure targeted therapeutics, complete with analysis by indications, stage of...